Real-World Study Confirms RSV Vaccine's, Arexvy and Abrysvo, Protective Power for Seniors
FRIDAY, Oct. 18, 2024 -- A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization.
With U.S. vaccination rates falling, "I...